Inflammatory Markers and Incident Heart Failure Risk in Older Adults. The Health ABC (Health, Aging, and Body Composition) Study

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2129-2137

  Kalogeropoulos, Andreas ^a   Georgiopoulou, Vasiliki ^a   Psaty, Bruce M ^b   Rodondi, Nicolas ^c   Smith, Andrew L ^a   Harrison, David G ^a   Liu, Yongmei ^d   Hoffmann, Udo ^e   Bauer, Douglas C ^f   Newman, Anne B ^g   Kritchevsky, Stephen B ^d   Harris, Tamara B ^h   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d WAKE FOREST UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

elderly; heart failure; inflammation

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; BODY COMPOSITION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEALTH STATUS; HEART FAILURE; HUMANS; INCIDENCE; INTERLEUKIN-6; MALE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951639762     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.045     Document Type: Article

References (55)

1. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., and Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
2. Tsutamoto T., Hisanaga T., Wada A., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
3. Roig E., Orus J., Pare C., et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 82 (1998) 688-690
4. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
5. Miettinen K.H., Lassus J., Harjola V.P., et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 10 (2008) 396-403
6. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
7. Raymond R.J., Dehmer G.J., Theoharides T.C., and Deliargyris E.N. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 141 (2001) 435-438
8. Kosmala W., Derzhko R., Przewlocka-Kosmala M., Orda A., and Mazurek W. Plasma levels of TNF-alpha, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis 19 (2008) 375-382
9. Williams E.S., Shah S.J., Ali S., Na B.Y., Schiller N.B., and Whooley M.A. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 10 (2008) 63-69
10. El-Menyar A.A. Cytokines and myocardial dysfunction: state of the art. J Card Fail 14 (2008) 61-74
11. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
12. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108 (2003) 2317-2322
13. Bahrami H., Bluemke D.A., Kronmal R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51 (2008) 1775-1783
14. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score. Circ Heart Fail 1 (2008) 125-133
15. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
16. van der Meer I.M., de Maat M.P., Bots M.L., et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 22 (2002) 838-842
17. Greenfield J.R., and Campbell L.V. Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?. Curr Diabetes Rev 2 (2006) 195-211
18. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., Wesseling G., and Wouters E.F. Systemic effects of smoking. Chest 131 (2007) 1557-1566
19. Annuk M., Soveri I., Zilmer M., Lind L., Hulthe J., and Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 18 (2005) 721-726
20. Wong L.Y., Leung R.Y., Ong K.L., and Cheung B.M. Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene -572C>G polymorphism in subjects with and without hypertension. J Hum Hypertens 21 (2007) 875-882
21. Don B.R., and Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial 17 (2004) 432-437
22. Fried L.P., Borhani N.O., Enright P., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1 (1991) 263-276
23. Li R., Nicklas B., Pahor M., et al. Polymorphisms of angiotensinogen and angiotensin-converting enzyme associated with lower extremity arterial disease in the Health, Aging and Body Composition study. J Hum Hypertens 21 (2007) 673-682
24. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
25. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008) 2456-2467
26. Wang J., and Nagueh S.F. Current perspectives on cardiac function in patients with diastolic heart failure. Circulation 119 (2009) 1146-1157
27. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007) 928-935
28. Volinsky C.T., and Raftery A.E. Bayesian information criterion for censored survival models. Biometrics 56 (2000) 256-262
29. Wagenmakers E.J. A practical solution to the pervasive problems of p values. Psychon Bull Rev 14 (2007) 779-804
30. van Buuren S., Boshuizen H.C., and Knook D.L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18 (1999) 681-694
31. Ambler G., Omar R.Z., and Royston P. A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome. Stat Methods Med Res 16 (2007) 277-298
32. Barnard J., and Rubin B. Small-sample degrees of freedom with multiple imputation. Biometrika 86 (1999) 948-955
33. Barker W.H., Mullooly J.P., and Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113 (2006) 799-805
34. McCullough P.A., Philbin E.F., Spertus J.A., Kaatz S., Sandberg K.R., and Weaver W.D. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39 (2002) 60-69
35. Curtis L.H., Whellan D.J., Hammill B.G., et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 168 (2008) 418-424
36. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
37. Levy D., Kenchaiah S., Larson M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 (2002) 1397-1402
38. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 (2004) 344-350
39. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., and Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257 (1992) 387-389
40. Muller-Werdan U., Schumann H., Fuchs R., et al. Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol 29 (1997) 2915-2923
41. Janssen S.P., Gayan-Ramirez G., Van den Bergh A., et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 111 (2005) 996-1005
42. Hirota H., Yoshida K., Kishimoto T., and Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A 92 (1995) 4862-4866
43. Bozkurt B., Kribbs S.B., Clubb Jr. F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97 (1998) 1382-1391
44. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97 (1998) 1375-1381
45. Bradham W.S., Moe G., Wendt K.A., et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol 282 (2002) H1288-H1295
46. Verma S., Li S.H., Badiwala M.V., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
47. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
48. Zambon A., Gervois P., Pauletto P., Fruchart J.C., and Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 (2006) 977-986
49. Sciarretta S., Ferrucci A., Ciavarella G.M., et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 20 (2007) 784-791
50. Westermann D., Van Linthout S., Dhayat S., et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 102 (2007) 500-507
51. Van Linthout S., Riad A., Dhayat N., et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50 (2007) 1977-1986
52. Kumar A., and Cannon C.P. The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Fail Clin 4 (2008) 129-139
53. Udell J.A., and Ray J.G. Primary and secondary prevention of heart failure with statins. Expert Rev Cardiovasc Ther 4 (2006) 917-926
54. Liao Y., Zhao H., Ogai A., et al. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 31 (2008) 335-344
55. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873